Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-25
2006-04-25
Wang, Andrew (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S325000, C435S375000, C536S023100, C536S023200, C536S024330, C536S024500
Reexamination Certificate
active
07034009
ABSTRACT:
The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.
REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5334711 (1994-08-01), Sproat et al.
patent: 5359051 (1994-10-01), Cook et al.
patent: 5525468 (1996-06-01), McSwiggen
patent: 5589332 (1996-12-01), Shih et al.
patent: 5631359 (1997-05-01), Chowrira et al.
patent: 5672695 (1997-09-01), Eckstein et al.
patent: 5741679 (1998-04-01), George et al.
patent: 5834186 (1998-11-01), George et al.
patent: 5871914 (1999-02-01), Nathan
patent: 360257 (1990-03-01), None
patent: WO8902439 (1989-03-01), None
patent: WO9103162 (1991-03-01), None
patent: WO9207065 (1991-09-01), None
patent: WO9312569 (1993-04-01), None
patent: WO9315187 (1993-08-01), None
patent: WO9323057 (1993-11-01), None
patent: WO9402595 (1994-02-01), None
patent: WO9411499 (1994-05-01), None
patent: WO9421679 (1994-09-01), None
patent: WO9421791 (1994-09-01), None
patent: WO9511304 (1994-10-01), None
patent: WO9504142 (1995-02-01), None
patent: WO9504818 (1995-02-01), None
patent: WO9506731 (1995-03-01), None
patent: WO9511910 (1995-05-01), None
patent: WO9513380 (1995-05-01), None
patent: WO9521868 (1995-08-01), None
patent: WO9523225 (1995-08-01), None
patent: WO9610390 (1996-04-01), None
patent: WO9610391 (1996-04-01), None
patent: WO9610392 (1996-04-01), None
patent: WO9622689 (1996-08-01), None
patent: WO9700957 (1997-01-01), None
patent: WO9726270 (1997-07-01), None
patent: WO9813526 (1998-04-01), None
patent: WO9827104 (1998-06-01), None
patent: WO9828317 (1998-07-01), None
patent: WO9858058 (1998-12-01), None
patent: WO9904819 (1999-02-01), None
patent: WO9916871 (1999-04-01), None
patent: WO9929842 (1999-06-01), None
patent: WO9955857 (1999-11-01), None
patent: WO0024931 (2000-05-01), None
patent: WO0026226 (2000-05-01), None
Parry et al. Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic Acids Research, 1999 vol. 27:2569-2577.
Branch, A. A Good Antisense is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells, 2000, vol. 18:307-319.
Dias et al. Potential roles of antisense oligonucleotides in cancer therapy. The example of bcl-2 antisense oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics, 2002 vol. 54:263-269.
Ma et al. Synthetic oligonucleotides are therapeutics: the coming of age. Biotechnology Annual Review, 2000 vol. 5:155-196.
Usman et al., “Chemical modification of hammerhead ribozymes: activity and nuclease resistance,”Nucleic Acids Syposium Series31:163-164 (1994).
Parry et al. 1999. “Bioactivity of anti-angiogenic ribozymes targetingFlt-1 andKDRmRNA,”Nucleic Acid Res.27:2569-77.
Aiello et al., “Suppression of Retinal Neovascularization in vivo by inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins,”Proc. Natl. Acad. Sci. USA92: 10457-10461 (1995).
Aiello, et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders,” 1994New Engl. J. Med.331, 1480.
Akhtar and Juliano, “Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides,”Trends Cell Biol.2:139-144 (1992).
Bartel and Szostak, “Isolation of New Ribozymes From a Large Pool of Random Sequences,”Science261:1411-1418 (1993).
Beaucage and lyer, “The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives,”Tetrahedron49:1925-1963 (1993).
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes,”J. Biol. Chem.270:25702-25708 (1995).
Berkman et al., “Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms,” 1993J. Clini. Invest.91, 153.
Breaker and Joyce, “Inventing and improving ribozyme function: rational design versus iterative selection methods,”TIBTECH12:268-275 (1994).
Breaker et al., “A DNA enzyme with Mg2-dependent RNA phosphoesterase activity,”Chemistry&Biology2(10):655-660 (1995).
Breaker, “Are engineered proteins getting competition from RNA?”Current Opinion in Biotechnology7:442-448 (1996).
Burger et al., “Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation,”Cornea4:35-41 (1985/1986).
Burgin et al., “Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates,”Biochemistry35:14090-14097 (1996) (volume no mistakenly listed as 6).
Carter, “Adeno-Associated Virus Vectors,”Curr. Opi. Biotech.3:533-539 (1992).
Caruthers et al., “Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs,”Methods in Enzymology211:3-19 (1992).
Cech, “Ribozymes and Their Medical Implications,”JAMA260:3030-3034 (1988).
Chartrand et al., “An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain,”Nucleic Acids Research23(20):4092-4096 (1995).
Chen et al., “Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates,”Nucleic Acids Research20:4581-4589 (1992).
Chowrira et al., “In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes,”J. Biol. Chem.269:25856-25864 (1994).
Christoffersen and Marr, “Riobozymes as Human Therapeutic Agents,”J. Med. Chem.38:2023-2037 (1995) (also referred to as Christofferson and Marr).
Cload and Schepartz, “Polyether Tethered Oligonucleotide Probes,”J. Am. Chem. Soc.113:6324-6326 (1991).
Collins and Olive, “Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived FromNeurosporaVS RNA,”Biochemistry32:2795-2799 (1993).
Detmar et al., “Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasisi,” 1994J. Exp. Med.180, 1141.
Dreyfus, “Restriction Ribozymes?”Einstein Quarterly Journal of Biology and Medicine6:92-93 (1988).
Dropulic et al., “Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression,”Journal of Virology66:1432-1441 (1992).
Durand et al., “Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability,”Nucleic Acids Research18:6353-6359 (1990).
Duval-Valentin, “Specific inhibition of transcription by triple helix-forming oligonucleotides,”Proc. Natl. Acad. Sci. USA89:504-508 (1992).
Egholm et al., “PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules,”Nature365:566-568 (1993).
Elkins and Rossi, “Ch. 2—Cellular Delivery of Ribozymes,” inDelivery Strategies for Antisense Oligonucleotide Therapeutics, edited by Akhtar, CRC Press, pp. 17-220 (1995).
Elroy-Stein and Moss, “Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells,”Proc. Natl. Acad. Sci. USA87:6743-6747 (1990).
Fava et al., “Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue,” 1994J. Exp. Med.180, 341.
Feldstein et al., “Two sequences participating in the autolytic
Escobedo Jaime
McSwiggen James
Pavco Pamela
Stinchcomb Dan
Chiron Corporation
Gibbs Terra
McDonnell Boehnen & Hulbert & Berghoff LLP
Sirna Therapeutics, Inc.
Wang Andrew
LandOfFree
Enzymatic nucleic acid-mediated treatment of ocular diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzymatic nucleic acid-mediated treatment of ocular diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzymatic nucleic acid-mediated treatment of ocular diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554463